



**WE CLAIM:**

1. A method for treating or preventing an allergic skin condition or an allergic ocular  
5 condition in a subject, comprising administering one or more histamine H1 receptor antagonists and one or more histamine H3 receptor antagonists to the subject.
2. The method of claim 1 wherein a histamine H1 receptor antagonist and a histamine H3  
10 receptor antagonist are administered along with a pharmaceutically acceptable carrier in a pharmaceutical composition.
3. The method of claim 1, wherein a histamine H1 receptor antagonist and a histamine  
H3 receptor antagonist are present in a single dosage form.
- 15 4. The method of claim 1, wherein a histamine H1 receptor antagonist and a histamine  
H3 receptor antagonist are administered in separate dosage forms.
5. The method of claim 1, wherein a histamine H1 receptor antagonist is one or more  
members selected from the group consisting of astemizole, azatadine, azelastine,  
20 acrivastine, brompheniramine, chlorpheniramine, clemastine, cyclizine, carebastine,  
cyproheptadine, carbinoxamine, desloratadine, doxylamine, diphenhydramine, cetirizine,  
dimenhydrinate, dimethindene, ebastine, epinastine, efletirizine, fexofenadine,  
hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin,  
norebastine, meclizine, norastemizole, picumast, pyrilamine, promethazine, terfenadine,  
25 tripeleminamine, temelastine, trimeprazine, triprolidine and





6. The method of claim 1, wherein a histamine H3 receptor antagonist is one or more  
members selected from the group consisting of thioperamide, impromidine,






burimamide, clobenpropit, impentamine, mifetidine, clozapine, S-sopromidine, R-sopromidine, ciproxifam,












5
















10










10








and



7. The method of claim 1 wherein the subject is administered chlorpheniramine and an antagonist selected from thioperamide and clobenpropit.






- 5 8. The method of claim 1 wherein a histamine H1 receptor antagonist and a histamine H3 receptor antagonist is administered to the subject parenterally.

9. The method of claim 1 wherein a histamine H1 receptor antagonist and a histamine H3 receptor antagonist is administered to the subject non-parenterally.
10. The method of claim 10 wherein a histamine H1 receptor antagonist and a histamine H3 receptor antagonist is administered to the subject topically.
11. The method of claim 1 wherein a histamine H1 receptor antagonist and a histamine H3 receptor antagonist are administered along with an additional agent selected from a non-steroidal anti-inflammatory drug, a steroid and an antibiotic.
12. The method of claim 1 wherein the subject is a human.
13. The method of claim 1 wherein the allergic skin condition is urticaria.
14. The method of claim 1 wherein the allergic ocular condition is selected from hay fever conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis.
15. A combination comprising:
- (a) one or more histamine H1 receptor antagonists; in association with
- (b) one or more histamine H3 receptor antagonists.
16. The combination of claim 15 wherein a histamine H1 receptor antagonist is one or more members selected from the group consisting of astemizole, azatadine, azelastine, acrivastine, brompheniramine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, desloratadine, doxylamine, diphenhydramine, cetirizine, dimenhydrinate, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, norebastine, meclizine, norastemizole, picumast, pyrillamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine, triprolidine and





















17. The combination of claim 15 wherein a histamine H1 receptor antagonist is one or more members selected from the group consisting of loratadine, desloratadine,  
5 chlorpheniramine, fexofenadine, promethazine, diphenhydramine and cetirizine.


18. The combination of claim 15 wherein a histamine H3 receptor antagonist is one or more members selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, clozapine, S-sopromidine, R-  
10 sopromidine, ciproxifam,



















and



19. A pharmaceutical composition comprising a combination of claim 15 along with a pharmaceutically acceptable carrier.

5 20. The composition of claim 19 which is in the form of a pill, capsule or tablet.